title: Predicted neoantigen load in non-hypermutated endometrial cancers: Correlation with outcome and tumor-specific genomic alterations.
abstract: Elevated neoantigen load has been previously correlated with improved outcome and response to immune checkpoint blockade in various tumor types. In endometrial cancer, previous studies of neoantigen load prediction have shown that the hypermutated MSI andPOLE-mutated tumors harbor significantly higher predicted neoantigen load compared to the hypomutated CN-low/endometrioid and CN-high/serous-like tumors. Here, we report that predicted neoantigen load may be a prognostic factor in hypomutated endometrial cancers, both in CN-low/endometrioid and CN-high/serous-like tumors. Specifically, in the TCGA dataset, CN-low/endometrioid tumors with neoantigen load in the highest tertile were associated with significantly improved progression free survival (PFS) (p = 0.031), while CN-high/serous-like tumors with neoantigen load in the lowest tertile were associated with worse PFS (p = 0.041). Importantly, certain tumor-specific genomic alterations were enriched in tumors with lower neoantigen load, includingCTNNB1mutations in CN-low/endometrioid tumors andMYCamplification andPIK3CAmutations in CN-high/serous-like tumors. These findings suggest that predicted neoantigen load and specific genomic alterations (such asCTNNB1mutations,MYCamplification andPIK3CAmutations) may be biomarkers of response to immunotherapy in hypomutated endometrial cancers, and argues that these exploratory biomarkers should be incorporated in clinical trials of immune checkpoint blockade in this disease.
authors.affiliation: The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, USA.
authors.forename: Sachet A
authors.initials: SA
authors.lastname: Shukla
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, USA.
authors.forename: Brooke E
authors.initials: BE
authors.lastname: Howitt
authors.affiliation: The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, USA.
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Wu
authors.affiliation: Medical Gynecologic Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, USA.
authors.forename: Panagiotis A
authors.initials: PA
authors.lastname: Konstantinopoulos